FIELD: medicine; pediatrics.
SUBSTANCE: invention can be used to diagnose the severity of acute infectious mononucleosis caused by the Epstein-Barr virus in children by biochemical analysis of blood serum. In patients with infectious mononucleosis caused by the Epstein-Barr virus, the content of fractalkine is determined. When the content of fractalkine in the blood serum ranges from 2.1 to 12.0 ng/ml, the severity of the condition is assessed as mild. When the content of fractalkine is in the range from 12.1 to 37.0 ng/ml, the severity of the condition is assessed as moderate. When the content of fractalkine is higher than 37.1 ng/ml, the severity is assessed as severe.
EFFECT: method helps to increase the reliability and expand the functionality of determining the severity of acute infectious mononucleosis caused by the Epstein-Barr virus by determining the content of fractalkine in the blood serum.
1 cl, 1 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF ASSESSING THE SEVERITY OF ACUTE INFECTIOUS MONONUCLEOSIS CAUSED BY THE EPSTEIN-BARR VIRUS IN CHILDREN | 2022 |
|
RU2798079C1 |
METHOD FOR SEVERITY DETERMINATION FOR ACUTE INFECTIOUS MONONUCLEOSIS CAUSED BY EPSTEIN - BARR VIRUS IN CHILDREN | 2016 |
|
RU2625505C1 |
DIAGNOSTIC TECHNIQUE OF SEVERITY OF EPSTEIN-BARR VIRUS INDUCED ACUTE INFECTIOUS MONONUCLEOSIS IN CHILDREN | 2011 |
|
RU2471196C1 |
METHOD OF FORECASTING SERIOUSNESS OF INFECTIOUS MONONUCLEOSIS OF VARIOUS ETIOLOGY AT CHILDREN | 2008 |
|
RU2360255C1 |
METHOD OF DIFFERENTIAL DIAGNOSTICS OF INFECTIOUS MONONUCLEOSIS OF VARIOUS ETIOLOGY AT CHILDREN | 2008 |
|
RU2360254C1 |
METHOD FOR INFECTIOUS MONONUCLEOSIS SEVERITY DIAGNOSTICS | 2017 |
|
RU2638801C1 |
METHOD OF ASSESSING THE QUALITY OF RECONVALESCENCE IN INFECTIOUS MONONUCLEOSIS IN CHILDREN | 2018 |
|
RU2703705C1 |
METHOD FOR ASSESSING DEGREE OF INFECTIOUS MONONUCLEOSIS IN CHILDREN | 2017 |
|
RU2673073C1 |
METHOD FOR PREDICTING THE FLOW OF INFECTIOUS MONONUCLEOSIS CAUSED WITH EPSTEIN-BARR VIRUS IN CHILDREN | 2005 |
|
RU2285262C1 |
METHOD FOR ASSESSING EFFECTIVENESS OF ANTIVIRAL THERAPY IN INFECTIOUS MONONUCLEOSIS IN CHILDREN | 2023 |
|
RU2821177C1 |
Authors
Dates
2023-06-13—Published
2022-12-27—Filed